Results 81 to 90 of about 6,579 (240)

Radioembolization for the treatment of hepatocellular carcinoma [PDF]

Clinical and Molecular Hepatology, 2017
Transarterial radioembolization (TARE) with yttrium 90 (90Y), an intra-arterial procedure performed by interventional radiologists, has begun being utilized in managing hepatocellular carcinoma (HCC) in Korea. There are two available TARE products: glass
Hyo-Cheol Kim
doaj   +1 more source

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib [PDF]

, 2013
Purpose: Yttrium-90 radioembolization (RE) is a locoregional therapy option for hepatocellular carcinoma (HCC). Sorafenib is a multikinase inhibitor used in HCC that can potentially affect the efficacy of RE by altering tumor vascularity or suppressing ...
Bazylewicz, Michael, He, Aiwu Ruth, Ju, Andrew Wenhua, Kallakury, Bhaskar, Lee, Justin S., NC DOCKS at East Carolina University, Rana, Nitesh, Unger, Keith R.   +7 more
core   +2 more sources

Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages [PDF]

Seminars in Interventional Radiology, 2017
AbstractTransarterial chemoembolization (TACE) is a well-established treatment for hepatocellular carcinoma (HCC). TACE has a clearly delineated role within the Barcelona Clinic Liver Cancer (BCLC) staging framework, and TACE has been shown to bridge patients to transplantation and to downsize patients' tumor burden to meet transplantation criteria ...
Joseph, Titano, Amir, Noor, Edward, Kim
openaire   +2 more sources

Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? [PDF]

, 2010
Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10-15% of HCC patients are suitable candidates for hepatic resection and liver transplantation due to the advanced ...
Beatrijs A. Seinstra, Otto M. van Delden, Karel J. van Erpecum, Richard van Hillegersberg, Willem P. Th. M. Mali, Maurice A. A. J. van den Bosch   +5 more
core   +2 more sources

Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Many centers screen all recipients for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). This approach may add substantial burdens of cost, incidental findings, and, depending on the imaging modality, radiation and/or contrast‐induced complications. We created simple criteria to help clinicians identify low‐
Wesley Dixon, Shaun Chandna, Jordan S. Sack, Meagan Gray, Christina N. Brown, Sampath Poreddy, Kai Ha, Michael R. Schoech, Stephen D. Zucker   +8 more
wiley   +1 more source

Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection

Journal of Clinical Interventional Radiology ISVIR
Purpose Yttrium 90 (Y90) transarterial radioembolization (TARE) is effective for unresectable hepatocellular carcinoma (HCC) or to bridge/downstage before transplant; however, optimal patient selection is not well-described. This study aims to
Amelia Wong, Shirley Cheng, Anthony Herrera, Linda Wong   +3 more
doaj   +1 more source

Advances in the Diagnosis, Treatment, and Management of Liver Nodules: A Comprehensive Review

Portal Hypertension &Cirrhosis, Volume 4, Issue 4, Page 232-251, December 2025.
Liver nodules commonly occur due to various causes, some of which are malignant or may undergo malignant transformation, leading to disease progression or delayed detection in clinical practice. The widespread use of imaging methods has increased the detection rate of liver nodules. Furthermore, precision medicine techniques and artificial intelligence
Chang Gao, Dongyang Chen, Youpeng Chen
wiley   +1 more source

Intermediate hepatocellular carcinoma: current treatments and future perspectives [PDF]

, 2017
Current guidelines recommend transarterial chemoembolization (TACE) as the standard treatment of Barcelona-Clinic Liver Cancer (BCLC)-B patients. However, the long-term survival outcomes of patients managed with this technique do not appear fully ...
Bargellini, I., De Maria, N., De Simone, P., Dufour, J.-F, Goulis, I., Marinho, R. T.   +5 more
core  

Yttrium-90 radioembolization for the treatment of unresectable liver cancer: Results of a single center [PDF]

, 2014
Objective: To determine the effects of yttrium-90 (Y-90) resin microsphere radioembolization therapy on patients with unresectable liver cancer who do not benefit from chemotherapy.
Hakan Şat Bozcuk, Hakkı Timur Sindel, Metin Erkılıç, Özhan Özgür, Şeyda Gündüz   +4 more
core   +1 more source

Comparable 5‐Year Survival in People With and Without HIV Following Hepatocellular Carcinoma Diagnosis: A Multicenter Study

Liver International, Volume 45, Issue 12, December 2025.
ABSTRACT Background and Aims Conflicting data on hepatocellular carcinoma (HCC) survival in people with HIV (PWH) may depend on tumour aggressiveness and access to curative treatments. We compared outcomes of two HCC cohorts according to HIV status.
Massimo Iavarone, Eleonora Alimenti, Massimo Puoti, Hamid Hasson, Bianca Monti, Sherrie Bhoori, Francesco Peracchi, Alessia Siribelli, Marco Fava, Mariangela Bruccoleri, Marco Merli, Giulia Morsica, Annalisa De Silvestri, Paolo Bonfanti, Antonella Castagna, Alessandro Soria, Pietro Lampertico   +16 more
wiley   +1 more source